Market Overview

Loxo Oncology's Candidates Are 'Impressive,' Piper Jaffray Says In Bullish Initiation

Loxo Oncology's Candidates Are 'Impressive,' Piper Jaffray Says In Bullish Initiation
Related LOXO
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
Jim Cramer Shares His Thoughts On Alibaba, Caterpillar And More

Loxo Oncology Inc (NASDAQ: LOXO) is up 280 percent year-over-year — and, by one estimate, still has room to run.

The Rating

Piper Jaffray analyst Tyler Van Buren initiated coverage with an Overweight rating and a $200 price target.

The Thesis

Piper Jaffray sees promise in Loxo’s TRK fusion and RET alteration franchises. The analyst considers larotrectinib and LOXO-292 “impressive,” with the former serving as “the perfect proof of concept” and the latter demonstrating superior response rates to Blueprint Medicines Corp (NASDAQ: BPMC)’s BLU-667.

“In a short period, Loxo has become a leader in the precision medicine field, which is a reflection of the company's efficient approach to drug discovery and development,” Van Buren said in a Thursday note.

The analyst expects improved LOXO-292 data at the upcoming ASCO conference as well as larotrectinib’s regulatory approval in the fall, laying a foundation for a $1-billion-plus global franchise.

Altogether, with Loxo’s favorable results, Piper Jaffray anticipates near-term opportunity for a takeover.

“Given the data generated by the laro/195 and 292 programs, we believe that the promise of Loxo's approach to drug development is clear and that any significant player in oncology would benefit from the company's drug discovery platform.”

Price Action

Loxo shares were trading up 1.77 percent at $176.72 at the time of publication. 

Related Links:

Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics

'Right To Try' Law Signed By Trump Increases Patient Access To Experimental Drugs

Latest Ratings for LOXO

Oct 2018Morgan StanleyMaintainsOverweightOverweight
Sep 2018Leerink SwannInitiates Coverage OnOutperform
Sep 2018Goldman SachsInitiates Coverage OnNeutral

View More Analyst Ratings for LOXO
View the Latest Analyst Ratings

Posted-In: oncology Piper JaffrayAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (LOXO + BPMC)

View Comments and Join the Discussion!

Latest Ratings

AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Day Market Update: Dow Down Over 250 Points; Madrigal Pharmaceuticals Shares Spike Higher

This Indicator Says Shares Of Netflix Are Going To Keep Rising